What Fueled The Previous Growth In The Fatty Liver Treatment Market?
The fatty liver treatment market has seen considerable growth due to a variety of factors.
•In recent times, the fatty liver treatment market has seen significant growth. It is projected to increase from $23.73 billion in 2024 to $25.12 billion in 2025 with a compound annual growth rate (CAGR) of 5.8%.
Factors such as the obesity crisis, inactive lifestyles, poor dietary habits, few treatment alternatives, and awareness campaigns have contributed to the growth experienced in this period.
What Is The Expected Growth In The Fatty Liver Treatment Market Size?
The fatty liver treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for the treatment of fatty liver is predicted to witness substantial expansion in the upcoming years. It is anticipated to escalate to $33.07 billion by 2029, with a CAGR of 7.1%.
The projected growth during this period can be attributed to factors such as the rising incidence of the disease, increased spending on healthcare, a surge in diabetes and metabolic syndrome, and innovations in therapeutic procedures. Key trends expected during this period are accurate medicine approaches, lifestyle alteration programs, targeted therapies specifically designed for Nash, non-invasive surveillance equipment, and progressive technology.
What Are The Leading Drivers Of Growth In The Fatty Liver Treatment Market?
The fatty liver treatment market is predicted to expand due to a surge in alcohol intake. The term alcohol consumption denotes the act of ingesting alcoholic beverages, which have a psychoactive substance, alcohol, that has depressive impacts on the central nervous system. The disease of fatty liver could be exacerbated by alcohol consumption, resulting in more extreme liver conditions such as alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For example, the HRB National Drugs Library, a government-funded entity based in Ireland, reported in March 2023 that during 2022, the per capita alcohol consumption for individuals aged 15 and above in Scotland reached 10.2 liters of pure alcohol, demonstrating a 7.6% increase from 2021. This indicates a troubling upward pattern in alcohol intake despite continuous public health initiatives to decrease consumption. Thus, the rise in alcohol consumption is fuelling the expansion of the fatty liver treatment market.
How Are The Segments Defined Within The Global Fatty Liver Treatment Market?
The fatty liver treatment market covered in this report is segmented –
1) By Treatment Type: Anti-Rejection Drugs Or Immunosuppressants, Chemotherapy Drugs, Targeted Therapy, Vaccines, Anti-Viral Drugs
2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Anti-Rejection Drugs Or Immunosuppressants: Corticosteroids, Calcineurin Inhibitors, mTOR Inhibitors
2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation
3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies
4) By Vaccines: Therapeutic Vaccines, Preventive Vaccines
5) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs
Pre-Book The Fatty Liver Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Fatty Liver Treatment Market?
Product innovation is currently a significant trend emerging in the market for fatty liver treatment. Establishing innovative products is a primary method used by leading companies in the fatty liver treatment industry to fortify their market presence. For example, Akero Therapeutics, an American biotech firm, shared positive data from its Phase II trials for efruxifermin in March 2023. This product, used in the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), is a distinctive Fc-FGF21 fusion protein. It imitates the biological function of the fibroblast growth factor 21 (FGF21), which influences numerous metabolic pathways and cellular processes.
Who Are the Key Players in the Fatty Liver Treatment Market?
Major companies operating in the fatty liver treatment market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Hoffmann La Roche Ltd.
• AstraZeneca plc
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• The Bristol-Myers Squibb Company
• GlaxoSmithkline plc
• Mitsubishi Chemical Holdings
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Eisai Co. Ltd.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Limited
• GW Pharmaceuticals Limited
• Retrophin Inc.
• Alnylam Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc.
• AbbKine Scientific Co. Ltd.
• Daewoong Co. Ltd.
• Madrigal Pharmaceuticals Inc.
• Orchid Chemicals & Pharmaceuticals Limited
• Genfit
• NGM Biopharmaceuticals Inc.
• Cardax Inc.
• Conatus Pharmaceuticals Inc.
• Limerick Biopharma Inc.
What Is The Most Dominant Region In The Fatty Liver Treatment Market?
North America was the largest region in the fatty liver treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
